Repository logo

Magnetic resonance fingerprinting of the pancreas at 1.5 T and 3.0 T.

Accepted version



Change log


Serrao, Eva M 
Kessler, Dimitri A 
Carmo, Bruno 
Beer, Lucian 
Brindle, Kevin M 


Magnetic resonance imaging of the pancreas is increasingly used as an important diagnostic modality for characterisation of pancreatic lesions. Pancreatic MRI protocols are mostly qualitative due to time constraints and motion sensitivity. MR Fingerprinting is an innovative acquisition technique that provides qualitative data and quantitative parameter maps from a single free-breathing acquisition with the potential to reduce exam times. This work investigates the feasibility of MRF parameter mapping for pancreatic imaging in the presence of free-breathing exam. Sixteen healthy participants were prospectively imaged using MRF framework. Regions-of-interest were drawn in multiple solid organs including the pancreas and T1 and T2 values determined. MRF T1 and T2 mapping was performed successfully in all participants (acquisition time:2.4-3.6 min). Mean pancreatic T1 values were 37-43% lower than those of the muscle, spleen, and kidney at both 1.5 and 3.0 T. For these organs, the mean pancreatic T2 values were nearly 40% at 1.5 T and < 12% at 3.0 T. The feasibility of MRF at 1.5 T and 3 T was demonstrated in the pancreas. By enabling fast and free-breathing quantitation, MRF has the potential to add value during the clinical characterisation and grading of pathological conditions, such as pancreatitis or cancer.



Adult, Algorithms, Female, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Motion, Pancreas, Pattern Recognition, Automated, Phantoms, Imaging, Prospective Studies, Respiration

Journal Title

Sci Rep

Conference Name

Journal ISSN


Volume Title



Springer Science and Business Media LLC


All rights reserved
Cancer Research Uk (None)
Cancer Research UK (C12912/A27150)
Cancer Research UK (CB4100)
Cancer Research UK (C14303/A17197)
Cancer Research UK (C96/A25177)
European Commission Horizon 2020 (H2020) Industrial Leadership (IL) (761214)
This work has been funded by the Mark Foundation for Cancer Research and Cancer Research UK Cambridge Centre [CA685/A25177], the European Union's Horizon 2020 research and innovation programme under grant agreement no. 761214, the National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre and Addenbrooke’s Charitable Trust. D.A.K holds a GlaxoSmithKline Fellowship. E.C.P.M.S. is also supported by the Academy of Medical Sciences, the Wellcome Trust, the Medical Research Council (MRC), the British Heart 23Foundation, Versus Arthritis, Diabetes UK and the British Thoracic Society (Helen and Andrew Douglas bequest) Starter Grant award [SGL019\1007].